1.455

2.35% -0.035

After Hours: 1.47 0.015 +1.03%

Ocugen Inc (OCGN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Ocugen Inc stock is traded at $1.455, with a volume of 15.62M. It is down -2.35% in the last 24 hours and down -17.80% over the past month. Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Previous Close:

$1.49

Open:

$1.53

24h Volume:

15.62M

Relative Volume:

1.92

Market Cap:

$492.54M

Revenue:

$4.41M

Net Income/Loss:

$-67.85M

P/E Ratio:

-6.4438

EPS:

-0.2258

Net Cash Flow:

$-57.15M

1W Performance:

-13.39%

1M Performance:

-17.80%

6M Performance:

+5.43%

1Y Performance:

+103.44%

1-Day Range:

$1.45

$1.53

1-Week Range:

$1.45

$1.90

52-Week Range:

$0.64

$2.725

Ocugen Inc Stock (OCGN) Company Profile

Name

Ocugen Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

484-328-4701

Address

11 GREAT VALLEY PARKWAY, MALVERN, PA

Employee

116

Twitter

@Ocugen

Next Earnings Date

2026-05-05

Latest SEC Filings

OCGN's Discussions on Twitter

Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCGN Ocugen Inc	1.455	504.39M	4.41M	-67.85M	-57.15M	-0.2258
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Ocugen Inc Stock (OCGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-17-26	Initiated	Canaccord Genuity	Buy
Mar-11-26	Initiated	Oppenheimer	Outperform
Oct-15-24	Initiated	Maxim Group	Buy
Mar-01-23	Upgrade	Chardan Capital Markets	Neutral → Buy
Aug-23-22	Initiated	Mizuho	Buy
Jun-15-22	Resumed	ROTH Capital	Buy
Jun-02-22	Initiated	Cantor Fitzgerald	Overweight
Jul-26-21	Initiated	Noble Capital Markets	Outperform
Jun-11-21	Downgrade	ROTH Capital	Buy → Neutral
May-07-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-09-21	Downgrade	Chardan Capital Markets	Buy → Neutral
Feb-04-21	Upgrade	H.C. Wainwright	Neutral → Buy

View All

Ocugen Inc Stock (OCGN) Latest News

12:01 PM

OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook - Yahoo Finance

12:01 PM

Ocugen Inc (OCGN)

Ocugen Inc Stock (OCGN) Company Profile

Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC

Ocugen Inc Stock (OCGN) Upgrades & Downgrades

Ocugen Inc Stock (OCGN) Latest News

OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook - Yahoo Finance

Full Transcript: Ocugen Q1 2026 Earnings Call - Sahm

Ocugen’s Convertible Debt Deal Funds a Pipeline Push, but Investors Balk at Dilution Risk - AD HOC NEWS

Ocugen Q1 2026 Earnings Call Transcript - MarketBeat

Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch

Ocugen Q1 Earnings Call Highlights - Yahoo Finance

Ocugen stock plunges after gene therapy company announces $115M debt sale - The Business Journals

OCGN cash outlook extends to 2028 as OCU400 and OCU410ST enrollment completes - Traders Union

Ocugen stock dips as Q1 losses widen - MSN

Ocugen Advances Late-Stage Gene Therapies, Bolsters Cash Runway - TipRanks

Ocugen Provides Business Update with First Quarter 2026 Financial Results - Ocugen, Inc.

Ocugen (NASDAQ: OCGN) prices $115M 2034 convertible notes deal - Stock Titan

Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes - Ocugen, Inc.

Ocugen prices $115 million convertible notes offering at 6.75% By Investing.com - Investing.com Australia

Ocugen Prices $115 Million Convertible Senior Notes Offering - marketscreener.com

Earnings call transcript: Ocugen Q1 2026 misses EPS, beats revenue - Investing.com

Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance

Ocugen stock tumbles 17% after convertible notes offering - Investing.com

Ocugen (NASDAQ:OCGN) Beats Q1 Revenue Estimates but Widens Net Loss, Announces $115M Capital Raise to Fund Pipeline Through 2028 - ChartMill

Ocugen reports Q1 results, raises $115M in convertible notes - Investing.com

Ocugen reports Q1 results, raises $115M in convertible notes By Investing.com - Investing.com Canada

Ocugen, Inc. announces pricing of $115 million of 6.75% convertible senior notes - marketscreener.com

OCUGEN ($OCGN) Releases Q1 2026 Earnings - Quiver Quantitative

Ocugen: Q1 Earnings Snapshot - Barchart.com

OCGN: Strong clinical progress and extended cash runway position the pipeline for key regulatory milestones - TradingView

Ocugen says two blindness gene therapy trials are fully enrolled - Stock Titan

Ocugen prices $115 million convertible notes offering at 6.75% - Investing.com

Ocugen, Inc. Announces Pricing Of $115 Million Of 6.75% Convertible Senior Notes - TradingView

Ocugen, Inc. Announces Pricing of $115 Million Convertible Senior Notes Offering - Quiver Quantitative

Ocugen's $115M note deal sends $32.7M to repay Avenue loan - Stock Titan

Ocugen plans $115 million convertible notes offering By Investing.com - Investing.com South Africa

MSN Money - MSN

Ocugen’s $115 Million Convertible Play Buys Time for a Pivotal Pipeline Push - AD HOC NEWS

symbol__ Stock Quote Price and Forecast - CNN

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes - Ocugen, Inc.

Ocugen (OCGN) Plans $115 Million Private Offering of Convertible Notes - GuruFocus

Ocugen Inc. stock rises Monday, outperforms market - MarketWatch

Ocugen Announces Private Convertible Notes Offering to Deleverage - TipRanks

Ocugen issues $115M notes to repay debt; stock faces after-hours selling - MSN

Ocugen plans $115 million convertible notes offering - Investing.com

Ocugen (NASDAQ: OCGN) to issue $115M convertibles and repay Avenue loan - Stock Titan

OCGN Stock Price, Quote & Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill

Ocugen Inc. stock rises Friday, outperforms market - MarketWatch

Ocugen (OCGN) Completes Enrollment for Phase 2/3 Pivotal Trial of OCU410ST Gene Therapy - Insider Monkey

Ocugen (OCGN) Expected to Announce Earnings on Friday - MarketBeat

Ocugen’s Gene Therapy Trio Nears the Regulatory Finish Line - AD HOC NEWS

Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch

OCGN gene therapy pipeline: Key 2026-27 catalysts ahead - MSN

Ocugen’s $10 Price Target Hangs on a Tightrope of Clinical Data and Cash - AD HOC NEWS

Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch

Ocugen Inc Stock (OCGN) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to OCGN